Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
Type:
Application
Filed:
September 2, 2010
Publication date:
July 14, 2011
Applicants:
SANOFI-AVENTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Patrick MAILLIET, Angela MARINETTI, Myriem SKANDER
Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
Type:
Grant
Filed:
February 7, 2007
Date of Patent:
July 12, 2011
Assignee:
University of South Florida
Inventors:
Heidi Kay, Jay W. Palmer, Joseph A. Stanko, Said M. Sebti
Abstract: Disclosed is a method of inactivating or destroying viruses on a product or article surface coming into contact with a mammal, including man, said method comprising providing said surface with a viricidal activity obtained by incorporating into said product or article, or by coating said product or article with an effective amount of at least one viricide or a composition comprising at least one viricide, wherein said viricide comprises (i) elemental silver deposited on glass particles having a particle size of 5-50 ?m, said elemental silver being deposited in an amount of 0.5-5% by weight calculated on said glass particles, or (ii) a silver salt deposited on metal oxide particles having a particle size of 0.1-2 ?m, said silver salt being deposited in a weight ratio silver salt to metal oxide of between 10:90 and 70:30, and wherein said viricide is present in an amount corresponding to between 0.001 and 1 g elemental silver/kg of said product or article.
Abstract: Antiseptic compositions and kits containing a source of silver ions and menthol, which act in synergy such that a concentration of silver ions in the composition is substantially reduced, are disclosed. Further disclosed are uses of the antiseptic compositions as disinfectants and in the treatment of wounds.
Abstract: The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are attached. The present invention is also directed to methods for preparing the BIT/ZnO complexes, to BIT/ZnO complexes prepared by the novel methods, to methods for using the BIT/ZnO complexes to inhibit microbial growth or reduce the level of bacteria on the surface of a substrate, and to substrates protected to from microbial attack by being treated with the BIT/ZnO complexes. The present invention is further directed to compositions comprising 1,2-benzisothiazolin-3-one which has been immobilized with zinc oxide.
Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.
Type:
Application
Filed:
February 25, 2011
Publication date:
June 16, 2011
Applicant:
University of Kentucky Research Foundation
Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.
Type:
Application
Filed:
April 8, 2009
Publication date:
June 16, 2011
Inventors:
Martyn Earle, Ken Seddon, Manuela Gilea, Gabor Boberly, Brendan Gilmore, Sean Gorman, Martin McLaughlin
Abstract: The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings.
Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<?>, COS<?>, SO3<?>, PO3<2?>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.
Type:
Grant
Filed:
November 17, 2003
Date of Patent:
May 24, 2011
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Avigdor Scherz, Alexander Brandis, Ohad Mazor, Yoram Salomon, Hugo Scheer
Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.
Type:
Application
Filed:
July 20, 2006
Publication date:
May 5, 2011
Applicant:
KREATECH BIOTECHNOLOGY B.V.
Inventors:
Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
Abstract: Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (I) in high purity.
Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.
Type:
Application
Filed:
October 12, 2010
Publication date:
April 14, 2011
Applicant:
THE UNIVERSITY OF AKRON
Inventors:
Wiley J. YOUNGS, Matthew J. PANZNER, Carolyn L. CANNON
Abstract: The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from 4-[bis(2-chloroethyl)amino]-D,L-phenyl-alanine (sarcolysine), the hydrochloride thereof, N-(2-furanidil)-5-fluorouracil (tegafur) and aminocarbonylaziridine (leacadin) at acidic to neutral pH in a chloroform/methanol mixture.
Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.
Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.
Type:
Application
Filed:
July 24, 2008
Publication date:
February 17, 2011
Applicant:
ALFAMA - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda.
Inventors:
Sandra S. Rodrigues, Joao D. Seixas, Bruno Guerreiro, Nuno Miguel Penacho Pereira, Carlos C. Romao, Werner E. Haas, Isabel Maria de Sousa Goncalves
Abstract: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).
Type:
Application
Filed:
April 17, 2009
Publication date:
February 17, 2011
Inventors:
Andreas Meijer, Oskar Axelsson, Anders Brathe, Andreas Olsson, John Henrik Johansen, Duncan George Wynn
Abstract: In one embodiment the present invention relates to a method of treating cancerous cells in a mammal comprising the steps of administering to the cancerous cells an effective amount of a cyclic amine wherein the cyclic amine contains sulfur or nitrogen and the structure includes an interchealted metal ion.
Type:
Application
Filed:
June 14, 2006
Publication date:
February 17, 2011
Inventors:
Wiley J. Youngs, Claire A. Tessier, Doug A. Medvetz, Michael J. Taschner
Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
Type:
Grant
Filed:
July 1, 2004
Date of Patent:
February 15, 2011
Assignee:
Commissariat a l'Energie Atomique
Inventors:
Claudio Vita, Mireille Sauvage-Vita, legal representative, Fabio Vita, legal representative, Elena Vita, legal representative, Loïc Le Clainche, Véronique Monjardet
Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.
Type:
Grant
Filed:
February 25, 2010
Date of Patent:
February 8, 2011
Assignee:
Chromaceutical Advanced Technologies, Inc.
Abstract: Provided are formulations and methods for treating inflammatory bowel disease, including Crohn's disease, ulcerative colitis, and Johne's disease. The formulations provided comprise pharmaceutically acceptable gallium compounds; the methods provided comprise means of using such formulations in the treatment of inflammatory bowel disease and closely related disorders.
Abstract: Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient.
Type:
Application
Filed:
March 11, 2009
Publication date:
January 27, 2011
Applicants:
HOSHI UNIVERSITY, SYNSTAR JAPAN CO., LTD., SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE
Abstract: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
Type:
Application
Filed:
September 30, 2010
Publication date:
January 27, 2011
Applicant:
VERTEX PHARMACEUTICALS INCORPORATED
Inventors:
Hayley Binch, Michael Mortimore, Damien Fraysse, Alistair Rutherford
Abstract: Provided are nitroplatinum(IV) complexes containing a bidentate dicarboxylate ligand (e.g., oxalate) which maybe useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages.
Abstract: The present invention relates to combinations of hydroxypyrion compounds, and silver compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a hydroxypyrion compound selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine, rilopirox, or a salt thereof, together with one or more silver salts selected from silver acetate, silver alginate, silver azide, silver citrate, silver lactate, silver nitrate, silver perchlorate, silver sulfate, silver chloride, silver thiocyanate, silver-sodium-hydrogen-zirconium phosphate, silver sulfadiazine, silver cyclohexanediacetic acid and disilver 2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dione in respective proportions to provide a synergistic biocidal effect.
Type:
Application
Filed:
March 10, 2009
Publication date:
January 13, 2011
Inventors:
Jan Pieter Hendrik Bosselaers, Mark Arthur Josepha Van Der Flaas, Alex Raymond Albert Valcke
Abstract: A stabilised composition having antibacterial, antiviral and/or antifungal activity, said composition comprising silver ions and a ligand, characterised in that the composition comprises a complex of silver and a ligand selected from the group consisting of 5,5-disubstituted hydantoins in which the substituents do not comprise conjugated unsaturated bonds and barbituric acid and derivatives thereof stabilising silver ions against reduction to free silver in a hydrophilic environment, and that the composition has a solubility in water higher than 10 mg Ag/l is stable during sterilisation and retains the activity without giving rise to darkening or discoloration of the dressing during storage.
Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Type:
Application
Filed:
August 15, 2008
Publication date:
December 23, 2010
Applicant:
PURDUE RESEARCH FOUNDATION
Inventors:
Philip Stewart Low, Sumith A. Kularatne
Abstract: A structure comprises at least a porous body holding a substance releasably, comprising a capping member for keeping the substance inside the pore and/or on at least a part of the entire surface of the porous body, and a connecting member for connecting the porous body and the capping member separably, the connecting member comprising a biopolymer compound. A method for releasing a substance from the structure set forth comprises the steps of applying stimulation from outside to the structure, and cleaving at least one of the bonding between the connecting member and the capping member and the bonding between the connecting member and the porous member to make the substance releasable from the structure.
Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
Type:
Application
Filed:
July 13, 2010
Publication date:
December 16, 2010
Applicant:
UNIVERSITY OF SOUTH FLORIDA
Inventors:
HEIDI KAY, JAY W. PALMER, JOSEPH A. STANKO
Abstract: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
Type:
Application
Filed:
March 30, 2010
Publication date:
December 2, 2010
Inventors:
John W. Babich, Kevin B. Maresca, James F. Kronauge, JR.
Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.
Type:
Application
Filed:
November 26, 2008
Publication date:
December 2, 2010
Applicant:
Merck Frosst Canada Ltd.
Inventors:
Elise Isabel, Christophe Mellon, Christian Beaulieu
Abstract: To improve bioavailability of the catalytic metalloporphyrin-based SOD mimics Mn(III) 5,10,15,20-tetrakis[N-ethylpyridinium-2-yl]porphyrin (MnTE-2-PyP5+) and Mn(III) 5,10,15,20-tetrakis[N,N?-diethylimidazolium-2-yl]porphyrin (MnTDE-2-ImP5+), three new Mn(III) porphyrins, bearing oxygen atoms within side chains, were synthesized and characterized: Mn(III) 5,10,15,20-tetrakis[N-(2-methoxyethyl)pyridinium-2-yl]porphyrin (MnTMOE-2-PyP5+), Mn(III) 5,10,15,20-tetrakis[N-methyl-N?-(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTM,MOE-2-ImP5+) and Mn(III) 5,10,15,20-tetrakis[N,N?-di(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTDMOE-2-ImP5+). The catalytic rate constants for O2?? dismutation (and the related metal-centered redox potentials vs NHE) for the new compounds are: log kcat=8.04 (E1/2=+251 mV) for MnTMOE-2-PyP5+, log kcat=7.98 (E1/2=+356 mV) for MnTM,MOE-2-ImP5+ and log kcat=7.59 (E1/2=+365 mV) for MnTDMOE-2-ImP5+. At 30 ?M levels none of the new compounds were toxic, and allowed SOD-deficient E.
Type:
Application
Filed:
July 15, 2010
Publication date:
December 2, 2010
Inventors:
Ines Batinic-Haberle, Irwin Fridovich, Ivan Spasojevic
Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.
Type:
Application
Filed:
June 4, 2008
Publication date:
October 21, 2010
Applicant:
Ben-Gurion University of the Negev Research and Development Authority
Inventors:
Aviv Gazit, Shimon Slavin, Esther Priel, Sara Yitzchak
Abstract: Cobalt salts have been found to be particularly effective against H. pylori and may therefore be used to treat gastrointenstinal infection with this bacteria. The cobalt salts have the advantage of showing a good degree of selectivity for H. pylori over other Gram positive and Gram negative bacteria. Treatment with the cobalt salts may be carried out at the same time as conventional treatment with an antibiotic and/or a proton pump inhibitor.
Type:
Grant
Filed:
May 24, 2001
Date of Patent:
October 12, 2010
Assignee:
Pfylori Limited
Inventors:
Sylvaine Franciose Aline Bruggraber, Jonathan Joseph Powell
Abstract: The invention disclosed herein provides methods for diagnosing and treating diseases and/or conditions associated with dysregulated Stat3-mediated activity.
Type:
Grant
Filed:
December 23, 2005
Date of Patent:
October 5, 2010
Assignee:
University of South Florida
Inventors:
James Turkson, Richard Jove, Said M. Sebti
Abstract: This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are also disclosed in treatment of environmentally caused premature skin aging, via reductions in fine facial lines and wrinkles, increased tensile strength of the skin, and increased protection against sunlight via increased production of melanin. Therapeutic outcomes are improved when the copper-pigment complex is enclosed within submicron liposomes.
Type:
Application
Filed:
June 9, 2010
Publication date:
September 30, 2010
Inventors:
Peter Ladislaus Dorogi, David Bruce Vasily, John Patrick McCook
Abstract: A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induced premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation.
Type:
Application
Filed:
June 11, 2010
Publication date:
September 30, 2010
Inventors:
Peter Ladislaus Dorogi, David Bruce Vasily, John Patrick McCook
Abstract: Use of tellurium-containing compounds for treating conditions in which inhibition of caspase-1/interleuFkin-1? enzyme (ICE) is beneficial is disclosed.
Abstract: A method for enlarging a peripheral vein so as to facilitate venipuncture of the vein by topically applying a vasodilator salt compound to skin overlying the vein and permitting the salt compound to cause the vein to enlarge by causing the vein to fill with blood.
Abstract: There is provided a production method in which bis(nitrato)platinum complex, optionally in the concurrent presence of dihalo-platinum complex, and poly(ethylene glycol)-block-poly(glutamic acid) are used at specific ratios and reacted. Coordination compound of an anti-tumor platinum complex with a block copolymer having carboxyl groups on its side chains is efficiently produced.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
August 24, 2010
Assignees:
Nanocarrier Co., Ltd., The University of Tokyo
Abstract: Compounds for antimicrobial applications, and for treating bacterial and fungal infection are set forth. The compounds may include a metal complex incorporated into a biodegradable polymeric nanoparticle. Also, a method of treating bacterial and fungal infections in a mammal includes the steps of administering an effective amount of a silver(I) metal salt incorporated into a biodegradable polymeric nanoparticle.
Type:
Application
Filed:
July 22, 2008
Publication date:
August 19, 2010
Applicant:
THE UNIVERSITY OF AKRON
Inventors:
Wiley J. Youngs, Khadijah M. Hindi, Douglas A. Medvetz, Matthew Panzner, Claire Tessier
Abstract: The invention relates to application of compounds having a general structural formula: where R= ?Li, Na, K, R1=—H, —NH2, —Br, —Cl, —OH, —COOH, B=—N?, —CH?, Z=—CH?, —N?, A=—N? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—N?, A=—CH? at B=—CH?, Z=—CH?, A=—CH? at B=—CH?, Z=—N?, and/or their pharmacologically acceptable salts as an active ingredient having appropriate activity with respect to nitrergic and/or dopaminergic systems, in a pharmaceutical composition as neuroprotector for improvement of the cognitive function and for normalization of psychophysiological status, as well as for treatment of a wide spectrum of psychological diseases, cardiovascular diseases, diseases caused by substance abuse, and diseases caused by a hyperactive immune system in mammals including human beings.
Type:
Grant
Filed:
August 3, 2004
Date of Patent:
August 17, 2010
Inventors:
Valery Khazhmuratovich Zhilov, Sergei Vladimirovich Zhuravlev, Alexander Nikolaevich Markov, Vladimir Mikhailovich Polosin
Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
August 17, 2010
Assignee:
BioNumerik Pharmaceuticals, Inc.
Inventors:
Xinghai Chen, Pavankumar N. V. Petluru, Qiuli Huang, Kesavaram Narkunan, Frederick Hausheer
Abstract: Disclosed herein are novel platinum-based analogs with a single substituted azole ligand: RN?NR7, wherein the RN?NR7 functional group is covalently bonded to the platinum through nitrogen of NR7. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof.
Type:
Grant
Filed:
January 26, 2006
Date of Patent:
July 20, 2010
Assignee:
BioNumerik Pharmaceuticals, Inc.
Inventors:
Zejun Xiao, Harry Kochat, Frederick H. Hausheer
Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.
Type:
Application
Filed:
December 4, 2009
Publication date:
July 15, 2010
Inventors:
John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
Abstract: A method of treating impaired memory and/or cognitive function by administering one or more chromium complexes, for example chromium picolinate, to an individual in need of improved memory and/or cognitive function. This method is used to improve memory and/or cognitive function associated with various disorders, including Alzheimer's disease, dementia, and mild cognitive impairment (MCI). Chromium complexes for treating memory or cognitive impairment are also disclosed.
Abstract: A polysaccharide-based solid material including, in its mass, at least one active agent having bactericidal, fungal, insecticidal and/or flame-retardant properties, and at least one complexing agent and/or at least one polymeric matrix having a complexing agent. The active agent includes at least one compound selected from the group including boron, silica, aluminum, phosphorus, iodine, derivatives thereof, aluminosilicate derivatives, and mixtures thereof. The solid material is characterized by an improved stability and by reduced environmental impact, and makes it possible to prepare materials based on wood particles and woods having a particular resistance against environmental attacks such as moisture.
Type:
Application
Filed:
March 28, 2007
Publication date:
July 15, 2010
Inventors:
Louis Gastonguay, Michel Perrier, Paul-Étienne Harvey, Jean-Francois Labrecque, Michel Robitaille, André Besner
Abstract: Polyamine macrocyclic compounds, e.g. of 10 to 15 ring members and 3 to 6 ring amine nitrogens, linked through methylene groups to an aromatic moiety, show high selective activity against HIV.
Type:
Grant
Filed:
December 16, 1992
Date of Patent:
February 15, 2011
Assignee:
Genzyme Corporation
Inventors:
Gary J. Bridger, Sreenivasan Padmanbhan, Renato Skerlj, David M. Thornton